Related by context. All words. (Click for frequent words.) 77 Acute Myocardial Infarction 75 Infarction 73 Thrombolysis 70 Acute Coronary Syndromes 70 Percutaneous Coronary Intervention 70 Venous Thromboembolism 70 Acute Coronary Syndrome 70 Acute Ischemic Stroke 69 Infarct 69 Ischemic Stroke 69 Cardiovascular Events 69 Clinical Outcome 68 Myocardial Ischemia 68 Prospective Randomized 68 Acute Decompensated Heart Failure 68 Risk Stratification 68 Ischemic 68 Reperfusion 68 Left Ventricular 67 Patients Undergoing 67 Carotid Endarterectomy 67 Thrombotic 67 Severe Sepsis 67 Cardiovascular Outcomes 67 Randomized Evaluation 66 Multicenter 66 Adjuvant Chemotherapy 66 ST Segment Elevation 66 Unstable Angina 66 Autologous Stem Cell Transplantation 66 Multicenter Study 66 Heart Failure Patients 66 Cardiogenic Shock 66 Ventricular Tachycardia 66 Radiofrequency Ablation 66 Thromboembolism 66 Patient Outcomes 66 ExTRACT TIMI 65 Acute Myocardial 65 Adjuvant Therapy 65 Randomized Study 65 Elderly Patients 65 Patients Treated 65 Immunosuppression 65 Unfractionated Heparin 65 Occlusive Disease 65 Patency 65 Left Ventricular Dysfunction 65 Carotid Stenting 65 Diabetic Nephropathy 65 Intracranial Aneurysms 65 Aggressive Reduction 65 Val HeFT 65 Disease Progression 65 Prospective Multicenter 65 Cardiovascular Risk 65 Aortic Stenosis 65 Pooled Analysis 65 Renal Cell Carcinoma 65 Statin Therapy 64 Randomized Clinical Trial 64 Study Evaluating 64 Angiographic 64 Carotid 64 Renal Artery 64 Randomized Controlled Trial 64 Relapsing Multiple Sclerosis 64 Subgroup Analysis 64 Stent Implantation 64 Inflammatory Markers 64 Stent Thrombosis 64 Coronary Artery 64 Septic Shock 64 Cardiotoxicity 64 Dual Antiplatelet Therapy 64 Solid Tumors 64 Critical Limb Ischemia CLI 64 Placebo Controlled Trial 64 Combination Treatment 64 Progenitor Cells 64 Cardiac Resynchronization 64 STRIDE PD 64 Clinical Trial Results 64 Oral Fingolimod 64 Controlled Trial 64 Recurrent Stroke 64 Localized Prostate Cancer 64 Heart Failure Trial 64 Improves Survival 64 Myocardial Infarction Study 64 Lung Injury 64 Antiviral Therapy 64 Metastatic Prostate Cancer 64 Predict Risk 64 Intervention Trial 64 Newly Diagnosed Multiple Myeloma 64 Lp PLA 2 64 Pulmonary Arterial Hypertension 64 Prolongs Survival 64 Restenosis 64 Randomized Double Blind Placebo 64 Diabetic Patients 64 Radical Prostatectomy 63 Metastatic Renal Cell Carcinoma 63 Phase 2b Study 63 Pivotal Trial 63 Aortic Dissection 63 Liver Failure 63 Stent Restenosis 63 Relapsing Remitting Multiple Sclerosis 63 Postmenopausal Women 63 Ambulatory Blood Pressure 63 Randomised Controlled Trial 63 Neoadjuvant Chemotherapy 63 Coronary Artery Bypass Graft 63 Knee Osteoarthritis 63 Endovascular Treatment 63 Fibrosis 63 Hypotension 63 Coronary Angiography 63 Randomized Phase 63 Multicenter Trial 63 Myocardial 63 Breast Cancer Recurrence 63 Systolic Blood Pressure 63 Catheter Ablation 63 Cholesterol Levels SPARCL 63 Peripheral Arterial 63 Intracranial 63 Meta Analysis 63 Coronary Revascularization 63 Patients Treated With 63 Ischemia 63 Renal Transplantation 63 Reperfusion Injury 63 Platelet Inhibition 63 ST Elevation Myocardial 63 Non Alcoholic Steatohepatitis 63 Intracoronary 63 Sudden Cardiac Death 63 Myelodysplastic Syndromes 63 Controlled Study 63 Placebo Controlled Study 63 CT Angiography 63 Ischaemic 63 Antihypertensive 63 Hormone Receptor Positive 63 Prostatectomy 63 Outpatient Setting 63 Increased Mortality 63 Hypertensive Patients 62 Fracture Risk 62 Randomized Controlled Trials 62 Randomised 62 Improves Outcomes 62 Antiplatelet Therapy 62 Phase III Clinical Trial 62 Prognostic Significance 62 Prostate Cancer Recurrence 62 Phase III Trial 62 Venous Thrombosis 62 Total Knee Arthroplasty 62 Clopidogrel 62 Bone Metastases 62 Randomized Double Blind 62 Intracerebral Hemorrhage 62 Anti Tumor Activity 62 Non Responders 62 fosbretabulin 62 complement inhibitor eculizumab 62 Allogeneic 62 Hyperlipidemia 62 Rheumatoid Arthritis Patients 62 Chronic Sinusitis 62 Arrhythmias 62 Hip Fracture 62 Monotherapy 62 Abciximab 62 Soft Tissue Sarcoma 62 Randomized Comparison 62 Chronic Heart Failure 62 Tiotropium 62 Surgical Treatment 62 Combination Therapy 62 Pegylated Liposomal Doxorubicin 62 Improved Survival 62 Gene Mutation 62 Atrial 62 Chronic Myeloid Leukemia 62 II Clinical Trial 62 Depressive Symptoms 62 Stenting 62 Edge STudy 62 Dilated Cardiomyopathy 62 Decompensated Heart Failure 62 Cognitive Impairment 62 Improve Survival 62 EVEREST II 62 Neoadjuvant 62 Ranolazine 62 Clinical Trial Evaluating 62 Bivalirudin 62 Insulin Resistance 62 myocardial infarction 62 Hepatocellular Carcinoma 62 Novel Oral 62 Microalbuminuria 62 Aortic Valve 62 EURIDIS 62 Hemodialysis Patients 61 Subarachnoid hemorrhage 61 Systemic Lupus Erythematosus SLE 61 Observational Study 61 Long Term Efficacy 61 Malignant Melanoma 61 Clinical Efficacy 61 Prognostic Value 61 Prospective Randomized Trial 61 Treatment Outcome 61 Refractory Angina 61 Gastric Cancer 61 Treating Chronic 61 Lung Cancer Trial 61 Bucindolol 61 Aneurysm Repair 61 Acute Stroke 61 Carotid Revascularization Endarterectomy vs. 61 Subtypes 61 ECASS 61 Invasive Breast Cancer 61 Malignancy 61 XIENCE V PROMUS Stent 61 Patient Registry 61 Reduced Risk 61 Patients Receiving 61 myocardial infarction MI 61 Well Tolerated 61 unfractionated heparin UFH 61 VADT 61 Malignancies 61 multicenter randomized controlled 61 Advanced Renal Cell 61 Anthracycline 61 Overactive Bladder 61 Etiology 61 Anticoagulation 61 Atypical Hemolytic Uremic Syndrome 61 Drug Eluting Stents 61 Cardiac Function 61 Endarterectomy 61 Trandolapril 61 Adenoma Prevention 61 Natalizumab 61 Meets Primary Endpoint 61 multicentre randomized 61 Bevacizumab 61 Systematic Review 61 Hematological 61 Cognitive Function 61 Clinical Study 61 Chronic Renal Failure 61 Ventricular 61 Chronic Lymphocytic Leukemia 61 transcranial Doppler ultrasound 61 Unresectable 61 Relapsed Multiple Myeloma 61 Events MACE 61 Hypercholesterolemia 61 Hypertrophy 61 TRITON TIMI 61 COPERNICUS 61 rFVIIa 61 PICSO ® 61 periprocedural 61 Psychiatric Disorders 61 prospective multicenter study 61 Kidney Function 61 Pivotal Phase III 61 C Reactive Protein 61 Diffuse Large B 61 Systemic Lupus Erythematosus 61 Carcinoma 61 Randomized Controlled 61 Survival Benefit 61 ischemia driven 61 Mouse Model 61 RE LY ® 60 reinfarction 60 invasive aspergillosis 60 Reduces Mortality 60 Skeletal Muscle 60 Myelodysplastic Syndrome MDS 60 Aortic Valve Replacement 60 Lenalidomide 60 Artery Disease 60 Pediatric Patients 60 Preclinical Study 60 Phase IIa Clinical Trial 60 Pharmacokinetic 60 Castration Resistant Prostate Cancer 60 Renal dysfunction 60 Radiation Induced 60 Study Showed 60 Sustained Efficacy 60 Laryngeal Cancer 60 RE LY 60 Randomized Phase II 60 Genetic Markers 60 Insulin Therapy 60 myocardial ischemia 60 Digital Mammographic Imaging 60 Induction Therapy 60 Cell Lymphoma 60 Dose Ranging Study 60 Follicular Lymphoma 60 Renal Function 60 Polymorphism 60 Intravesical 60 Adenoma 60 Nesiritide 60 Coronary Artery Bypass Surgery 60 Hemolysis 60 Phase Ib Clinical Trial 60 Aggressive Drug Evaluation 60 Sipuleucel T 60 Phase 2b Clinical Trial 60 cardiac dysfunction 60 Metastatic Colorectal Cancer 60 acute coronary syndromes ACS 60 ONTARGET 60 Atherosclerotic 60 Mortality Risk 60 Endovascular Repair 60 MGd 60 Progressive Multifocal Leukoencephalopathy 60 Vascular Disease 60 TAXUS ATLAS 60 Orthostatic Hypotension 60 metastatic malignant 60 Metastatic Melanoma 60 BOLDER II 60 Renal Disease 60 Echocardiographic 60 Lipid Lowering Treatment 60 ASTEROID 60 substudy 60 Lung Function 60 Nicotine Vaccine 60 Acute Coronary 60 Hormone Refractory Prostate Cancer 60 See CLINICAL PHARMACOLOGY 60 Treated Patients 60 Effective Treatments 60 HSCT 60 Multicenter Randomized 60 unstable angina pectoris 60 Randomised Trial 60 Enoxaparin 60 Bone Mineral Density 60 Colorectal Cancer Patients 60 Safinamide 60 CLARITY TIMI 60 Investigational Drug 60 Valsartan 60 Eluting Stent 60 Study Demonstrates 60 Systolic Hypertension 60 Pivotal Phase 60 Statistically Significant 60 Decitabine 60 Drug Shows Promise 60 Diabetic Foot Ulcer 60 atherothrombotic disease 60 Versus Placebo 60 Coronary Artery Calcium 60 Hospitalized Patients 60 MR Angiography 60 Platelet Aggregation 60 myocardial infarction stroke 60 Appears Safe 60 Subgroup analysis 60 Congestive Heart Failure 60 Post Operative 60 acute myocardial infarction AMI 60 Dendritic Cells 60 ACE Inhibitors 60 Unstable angina 60 Critically Ill Patients 60 ILLUSTRATE 60 Nebulized 60 Thromboembolic 60 Molecular Mechanism 60 Dose Response 60 acute coronary syndrome 60 Insulin Glargine 60 Tyrosine Kinase Inhibitor 60 Glatiramer Acetate 60 Neoplasms 60 tirofiban 60 Low Dose 60 Fungal Infections 60 Mitral Regurgitation 60 Randomized Trials 60 Enzastaurin 60 Renal Anemia 60 Antigen Specific 60 Stenting Trial CREST 60 Chronic Hepatitis C 60 LV dysfunction 60 prospective observational 59 Randomized Double blind 59 Obese Patients 59 Squamous Cell Carcinoma 59 Arch Neurol 59 Signaling Pathway 59 Circulating Tumor Cells 59 Dyspnea 59 Adjuvant Treatment 59 Novel Mechanism 59 Lowers Risk 59 Metastases 59 MADIT II 59 Neuroprotection 59 Chronic Lymphocytic Leukemia CLL 59 Long Term Outcomes 59 JAK Inhibitor 59 Bladder Cancer 59 Relapsed Refractory 59 Diabetic Neuropathy 59 Clinical Outcomes 59 Renal Failure 59 Advanced Prostate Cancer 59 Breast Cancers 59 Anxiety Depression 59 Thrombolytic Therapy 59 Gene Variation 59 Mitotic 59 Phase IIb Trial 59 Cyclophosphamide 59 familial amyloidotic polyneuropathy FAP 59 Treatment Resistant 59 Hepatitis C Genotype 59 Leukemias 59 Is Well Tolerated 59 Cognitive Decline 59 Iron Overload 59 tumor lysis syndrome 59 Asymptomatic 59 Heart Failure 59 Differential Diagnosis 59 Cerebrovascular 59 Estrogen Receptor 59 Resection 59 Endometrial Cancer 59 GISSI 59 Newly Diagnosed 59 Zoledronic Acid 59 Coagulation 59 Glycemic Control 59 Evaluation WISE 59 Esophageal 59 Completes Enrollment 59 Stem Cell Transplants 59 thrombus aspiration 59 Arrhythmogenic 59 CK MB 59 Clinical Evaluation 59 Respiratory Distress 59 Lipid Levels 59 Prognostic Factors 59 Total Hip Arthroplasty 59 PAOD 59 Cardiovascular Risk Factors 59 Randomized Trial 59 systolic hypertension 59 Cancer Incidence Mortality 59 Phosphatase 59 Nymox NX 59 Antitumor Activity 59 Lesion 59 Myoblast 59 Improve Outcomes 59 NIDDM 59 Neuroprotective Effects 59 Pivotal Study 59 relapsing multiple sclerosis 59 Left Ventricular Hypertrophy 59 Malformations 59 Complicated Skin 59 Candesartan 59 randomized multicenter trial 59 prospective multicenter 59 Shows Promise Against 59 Increased Risk 59 Radiation Dose 59 Previously Treated 59 Pharmacokinetic Study 59 Advanced Melanoma 59 Epidermal Growth Factor Receptor 59 Investigational Agent 59 Advanced Colorectal Cancer 59 riociguat 59 Albuminuria 59 Prostatic 59 induce orthostatic hypotension 59 Complication Rates 59 Pioglitazone 59 Endothelial Function 59 #p# [003] 59 Sustained Virologic Response 59 atherothrombosis 59 Preclinical Data 59 Balloon Angioplasty 59 multicenter randomized placebo controlled 59 CHAMPION PCI 59 Multicentre 59 Placebo Controlled 59 Hemorrhagic Stroke 59 Medullary Thyroid Cancer 59 Phase 2a Clinical Trial 59 number NCT# ClinicalTrials.gov 59 Recurrence 59 Stenosis 59 Pulmonary Artery 59 Prophylactic Treatment 59 Antiviral Activity 59 Sirolimus Eluting Stent 59 Tumor Growth 59 Epoetin Alfa 59 Non Alcoholic Fatty 59 Anti Tumor 59 Treatment Reduces 59 Preterm Delivery 59 Multicenter Double 59 Transcatheter 59 Contrast Agent 59 Breast Cancer Patients 59 PEG IFN 59 Myelodysplastic Syndrome 59 Eculizumab 59 multicenter prospective 59 Anticancer Activity 59 ACUITY trial 59 Phase 2b Trial 59 ABCB1 59 nonfatal MI 59 Prostate Cancer Patients 59 Demonstrates Efficacy 59 Acute Heart Failure 59 Drug Candidate 59 Tumor Response 59 cinacalcet 59 Adverse Event 59 Proves Effective 59 Complete Remission 59 Drug Prevents 59 Endovascular Valve Edge 59 ipsilateral stroke 58 Hepatotoxicity 58 Cutaneous T 58 Liver Injury 58 Allergic Rhinitis 58 ischemic complications 58 Randomized Placebo Controlled Trial 58 LVSD 58 Clostridium difficile Infection 58 Clinical Outcomes Utilizing Revascularization 58 MEND CABG 58 esophageal carcinoma 58 Naive Patients 58 Cognitive Deficits 58 Fondaparinux 58 Autoimmune Disease 58 Prostate Cancers 58 Therapy Improves 58 ST elevation myocardial 58 liver transplant recipients 58 paroxysmal nocturnal hemoglobinuria 58 Acute Renal Failure 58 Nephropathy 58 Phase IIIb 58 Lung Cancer Patients 58 Diabetes Mellitus 58 Drug Eluting 58 Treatment Naive 58 T2DM 58 Comorbidity 58 Double Blind Placebo 58 Therapeutic Targets 58 NSABP B 58 Histological 58 Interferon Beta 58 Main Outcome Measure 58 fluvastatin 58 Arch Intern Med 58 #-# Full Text 58 Kidney Transplantation 58 Induction Chemotherapy 58 Cholinesterase Inhibitors 58 Bare Metal Stent 58 Chronic Constipation 58 Systemic Sclerosis 58 Therapeutic Efficacy 58 eplerenone 58 Epithelial 58 longitudinal cohort study 58 Single Dose 58 severe oral mucositis 58 Clinical Significance 58 Alkaline Phosphatase 58 Renal Impairment 58 subanalysis 58 #F FDG PET CT 58 Hemorrhagic 58 NSTEMI 58 Myocardial Infarction MI 58 Acute Coronary Syndromes ACS 58 Anticoagulant 58 Comorbidities 58 Patients Enrolled 58 Adjunctive 58 Hormone Therapy 58 Carcinomas 58 Feasibility Trial 58 Rosuvastatin 58 chronic thromboembolic pulmonary 58 Inhaled Corticosteroids 58 eptifibatide 58 Attenuates 58 neointimal hyperplasia 58 coronary revascularization 58 Demonstrates Positive 58 Chronic Bronchitis 58 Clinical Trial Data 58 #q#.# [001] 58 Adverse Outcomes 58 FDG-PET/CT 58 Cytotoxicity 58 Hepatic 58 Phase IIb Clinical Trial 58 recurrent glioblastoma multiforme 58 Interventional Procedures 58 Viral Suppression 58 Coronary Syndromes 58 Trial Evaluating 58 Cardiac Arrest Patients 58 Osteoarthritis Patients 58 Retreatment 58 Valve Replacement 58 Levels Linked 58 Suicidality 58 Antiangiogenic 58 Metabolic Efficiency 58 Catheter Associated 58 Exacerbation 58 Treatment Naive Patients 58 Long Term Survival 58 Peginterferon Alfa 2a 58 Liver Metastases 58 Double Blind Randomized 58 gefitinib Iressa 58 Proteinuria 58 Histopathological 58 Demonstrated Significant 58 Azacitidine 58 Protease Inhibitor 58 Aliskiren 58 Randomized Phase III 58 Minimally Invasive Treatment 58 Neurodegenerative Disease 58 Arimidex Tamoxifen Alone 58 Genotypes 58 Polymorphisms 58 left ventricular dysfunction 58 Intervention Effectiveness 58 cerebral vasospasm 58 Targeted Therapy 58 Valvular 58 Shows Promising 58 Orally Active 58 Lymphoid 58 rebleeding 58 Pharmacodynamics 58 Peripheral Artery Disease 58 Coronary Disease 58 Cardiac Resynchronization Therapy 58 Blood Clots 58 Lupus Nephritis 58 Diastolic Heart Failure 58 Gene Variant 58 Potent Inhibitor 58 pT2 58 NMIBC 58 HYVET 58 QTc prolongation 58 ATACAND 58 Papillary 58 Hematologic 58 Antiplatelet 58 Cancer Patients Treated 58 Kinase Inhibitors 58 Severe Asthma 58 Inflammatory Diseases 58 GOUT 58 Neurologic Disorders 58 Gene Variants 58 platelet reactivity 58 CARE HF 58 Xelox 58 NICE SUGAR 58 Patients Suffering 58 Recurrent Prostate Cancer 58 BERKELEY CA UroToday.com 58 Fluorouracil 58 Slow Progression 58 Dasatinib 58 bypass graft CABG surgery 58 Serious Adverse Events 58 Oxidative Stress 58 Clinical Trial 58 Tolerability 58 Diagnostic Criteria 58 Breast Cancer Cells 58 Angiogenic 58 Multiple Myeloma Patients 58 Genes Identified 58 Autoimmune Diseases 58 AA Amyloidosis 58 First Patient Enrolled 58 ritonavir boosted 58 Demonstrates Significant 58 Insulin Sensitivity 58 SYNTAX 58 Malignant Pleural Mesothelioma 58 Intracerebral 58 undergoing coronary artery 58 Lung Cancers 58 Cyclooxygenase 2 58 Idiopathic Pulmonary Fibrosis 58 Peginterferon 58 Histologic 58 Score TOS 58 ACE Inhibitor 58 Cardiovascular Mortality 58 Endothelial 58 Renal Insufficiency 58 multicenter randomized 58 Psychiatric Illness 58 PEGylated interferon beta 1a 58 Erythropoietic 58 multicenter Phase III 58 Virus Infection 58 Cerebrospinal Fluid 58 Macrophage 58 Cannabinoid 58 Sleep Disturbances 58 Phase III Pivotal Trial 58 Gastrointestinal Stromal Tumors 58 atypical Hemolytic Uremic Syndrome 58 Blind Placebo Controlled 58 Receptor Agonist 57 Therapeutic Effects 57 nonrandomized 57 Recurrent Breast Cancer 57 icatibant 57 Randomised Study 57 dual endothelin receptor antagonist 57 Novel Inhibitor 57 Pivotal Clinical Trial 57 Clinical Relevance 57 thromboembolic 57 Pharmacokinetics PK 57 Multiethnic Study 57 abacavir Ziagen 57 Nilotinib 57 Contrast Enhanced 57 Renal Cancer 57 cTnI 57 Hematopoietic 57 Myelofibrosis 57 essential thrombocythemia 57 Microvascular 57 Blood Cancers 57 Erosive 57 Polyneuropathy 57 Stem Cell Treatment 57 erlotinib Tarceva ® 57 Anticoagulants 57 hepatic cirrhosis 57 Brain Atrophy 57 HIV HCV coinfected 57 Kidney Transplant Recipients 57 Cardiac Arrhythmias 57 Peripheral Blood 57 Epratuzumab 57 Circulatory Support 57 HER2 overexpression 57 multivariate Cox 57 CHARISMA trial 57 Genetic Variations 57 acute PAO 57 Bare Metal Stents 57 Prevent Stroke 57 Neovascular Age Related Macular 57 candesartan cilexetil 57 Hemodynamic 57 randomized multicenter 57 Tumor Progression 57 Transplant Patients 57 Sorafenib HCC Assessment 57 surgically resected 57 landmark ATHENA trial 57 sunitinib Sutent 57 Plaque Psoriasis 57 bronchial hyperresponsiveness 57 Nonalcoholic Fatty Liver Disease 57 Stent Placement 57 ID NCT# 57 Intervention Effectiveness CATIE 57 Beta Amyloid 57 Dyslipidemia 57 Therapy Evaluation 57 Estrogen Therapy 57 Autologous 57 MADIT 57 Beta Blockers 57 Etanercept 57 Free Survival PFS 57 Bosutinib 57 intracoronary 57 Intravitreal 57 Initiate Phase 57 J Nutr 57 Endometrial 57 CIMZIA TM certolizumab pegol 57 PRoFESS 57 Biphasic 57 intracerebral hemorrhage 57 DEFER 57 Nonalcoholic Steatohepatitis 57 Cholesterol Lowering Drug 57 Pegylated Interferon 57 venous thromboembolic disease 57 multicenter multinational 57 stage IIIB 57 Eye Diseases 57 Multicenter Phase 57 Malignant Glioma 57 Nephrectomy 57 Androgen Deprivation Therapy 57 Tyrosine Kinase Inhibitors 57 Postoperative 57 Cell Adhesion 57 Oral Cavity 57 Confirms Efficacy 57 Kidney Failure 57 thrombolytic therapy 57 Blood Pressure Monitoring 57 Gene Linked 57 Acute Coronary Events 57 Bloodstream Infections 57 Catheterization 57 Teriflunomide 57 BARI 2D 57 Ancrod 57 Acute Pancreatitis 57 Infected Patients 57 #:#-# [031] 57 Protein Interactions 57 Virologic 57 B Cell Lymphoma 57 Hip Fractures 57 Cancer Recurrence 57 drug eluting stent implantation 57 Replacement Therapy 57 pan HDAC inhibitor 57 Colorectal Cancers 57 ENDEAVOR IV 57 FASEB J. 57 Genetic Variation 57 Benign Prostatic Hyperplasia 57 Phase 2a Trial 57 Sentinel Lymph Node Biopsy 57 Completes Patient Enrollment 57 Preclinical Models 57 Phase III randomized 57 Breast Cancer Metastasis 57 nicardipine 57 Prospective Cohort Study 57 hyperglycaemia 57 papillary renal cell carcinoma 57 Immune Responses 57 prospective randomized controlled 57 Implantable Defibrillator 57 soluble CD# ligand 57 contrast echocardiography 57 Skin Lesions 57 tachyarrhythmias 57 Investigational Treatment 57 hepatorenal syndrome 57 Major Adverse Cardiac 57 Viral Infections 57 Thiazolidinediones 57 valvular disease 57 Ejection Fraction 57 Arterial Disease 57 metastatic neuroendocrine tumors 57 Tumor Cells 57 Stress Induced 57 perioperative complications 57 PKC# 57 variceal bleeding 57 T1DM 57 pretransplant 57 ZACTIMA 57 Therapeutic Potential 57 Periodontal Disease 57 LHON 57 mycophenolate mofetil 57 Pharmacologic 57 Hepatitis C Virus 57 Enzyme Replacement Therapy 57 DAPT 57 nadolol 57 Chemotherapeutic Agents 57 CTEPH 57 somatostatin analog 57 SORT OUT III 57 Embolic 57 hypoperfusion 57 Related Mortality 57 Patellofemoral 57 Capsule Endoscopy 57 CYT# potent vascular disrupting 57 prospective observational cohort 57 Inhibits 57 National Oncologic PET 57 Genetic Variant 57 Respiratory Virus 57 Kaplan Meier analysis 57 immunohistochemical 57 coronary stenosis 57 colorectal adenoma 57 Oxidized LDL 57 Thrombus 57 VT VF 57 ptau 57 JAK2 V#F 57 Colorectal Adenomas 57 fondaparinux 57 Atherothrombosis 57 Hospital Acquired Pneumonia 57 Hyperkalemia 57 Pelvic Organ Prolapse 57 Vascular Disrupting Agent 57 Regenerative Cells 57 primary percutaneous coronary 57 Dose Escalation 57 Pharmacodynamic 57 lactate dehydrogenase LDH 57 Dialysis Outcomes 57 Genetic Marker 57 receptor antagonism 57 Cytochrome P# 57 Abdominal Fat 57 Transcatheter Aortic Valve Implantation 57 Long Lesion 57 Evoked 57 Researchers Identify 57 Endothelial Cells 57 multicentre 57 Signaling Pathways 57 Chronic Hepatitis B 57 Shows Efficacy 57 Predictive Value 57 Myocardial infarction 57 Contrast Agents 57 thromboembolism 57 Degarelix 57 Therapy Shows Promise 57 Lower Extremity 57 Cardiac Allograft Rejection 57 Survival Rates 57 transplantation HSCT 57 aneurysmal subarachnoid hemorrhage 57 Organ Rejection 57 revascularisation 57 Prolonged Survival 57 Robotic Assisted 57 Polymerase Inhibitor 57 Granted Orphan Drug 57 Hepatic Encephalopathy 57 pancytopenia 57 Clinical Antipsychotic Trials 57 Ovarian Cancer Patients 57 REMINDER ORLive Presents 57 Trial NLST 57 Delayed Graft Function 57 retrospective cohort